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Abstract 
Objective: The objective of this selective EBM review is to determine whether or not “Does 
exogenous melatonin improve quality of sleep in patients experiencing sleep disturbances 
secondary to chronic diseases?” 
Study Design: Three Randomized, placebo-controlled studies (RCT) published in 2010, 2013 
and 2008.  
Data Sources: All RCTs searched and located using PubMed database.  
Outcomes Measured: Clinical outcome for all three articles using quality of sleep or quality of 
life questionnaires such as the Leeds Sleep Evaluation. All of which evaluated POEMs, and were 
self reported by participants.  
Results: In a randomized control study (RCT) by Serfaty et al, sleep quality improved by 
lessening time needed to get to sleep, but was not specific to either the experimental or placebo 
group. The RCT by Russcher et al. also indicated that there was no significant increase in quality 
of life for participants given exogenous melatonin. Only the RCT by Koch et al. showed 
significant improvement in quality of sleep with the use of melatonin in participants by 
decreasing time needed to fall asleep, increasing sleep time and improving overall quality of 
sleep.  
Conclusions: The data obtained was insufficient to conclusively support the use of exogenous 
melatonin to alleviate sleep disturbances secondary to chronic disease. Two of the three RCTs 
included in this systematic review were not able to show significant data in support of the 
positive effects of exogenous melatonin on sleep patterns.  
Keywords: melatonin, depression, and hemodialysis 
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Introduction 
Melatonin plays an important role in the sleep regulation of human beings. It is a 
hormone that modulates sleep/wake cycles and can greatly diminish quality of life if levels are 
disturbed. It is one of the main external indicators of time during sleep/wake cycles and is 
stimulated by darkness and inhibited by light.1 Many diseases such as chronic kidney disease and 
depression can cause sleep disturbances due to changes in circadian rhythms. More specifically, 
affective disorders such as depression affect circadian rhythms by modulating melatonin levels.1 
In patients suffering from chronic kidney disease, hemodialysis can impede the nocturnal rise in 
melatonin concentration.2 Exogenous melatonin is widely available for purchase as an over the 
counter supplement in the United States, and is fairly inexpensive. This paper analyzes three 
randomized controlled studies that study the effects of exogenous melatonin on sleep 
disturbances caused secondarily due to chronic diseases.  
Sleep disturbances consume a great deal of healthcare resources worldwide every year. 
Although there is not much data regarding the number of healthcare visits per year caused by 
sleep disturbances, one article noted that patients reporting less than 5 hours of sleep per night 
had the highest healthcare utilization when compared to other groups with better quality of 
sleep.3 The same article also noted that sleep complaints are underreported by patients, and 
underdiagnosed by physicians, and therefore the healthcare utilization due to sleep disturbances 
is much higher than reported.3 Although not specific to patients suffering from chronic diseases, 
one study noted that general sleep disturbances and associated health effects cost an estimated 
$450 million dollars annually in Australia alone.4 Due to the large impact of sleep disturbances 
on the depletion of healthcare resources, the efficacy of exogenous melatonin as a treatment for 
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sleep disturbances caused by they many different existing chronic disease is an important area of 
study.   
Currently there are a wide variety of methods used to treat sleep disturbances. Good sleep 
hygiene should be considered the first and simplest method of helping to lessen such sleep 
disturbances. Some practices that may improve sleep hygiene include, having a regular sleep 
schedule, avoiding caffeinated beverages or smoking in the evening, adjusting your sleep 
environment to decrease stimuli, and only exercising at least 4-5 hours before scheduled sleep.5 
Other non-pharmacological approaches can also be therapeutic towards improving quality of 
sleep. One such approach is to use relaxation techniques such as progressive muscle relaxation 
and relaxation response therapy that should implemented right before each intended sleeping 
period.5 Such relaxation techniques are simple to teach patients, and can be done independently. 
Cognitive behavioral therapy, which can be conducted traditionally through in person sessions or 
even via telephone or computer, may be an appropriate treatment for those individuals who need 
assistance and guidance. The most commonly used method to treat sleep disturbances are 
pharmacologic agents however. There are many different classes that can be utilized, including 
but are not limited to benzodiazepines, non-benzodiazepines, and melatonin agonists.6 Some 
common benzodiazepines used are triazolam, lorazepam, tenazepam, and alprazolam. Non-
benzodiazepines have newer, more advertised agents such as Zolpidem. Melatonin agonists 
agents include Ramelteon, and have shown to significantly improve general sleep latency.5 
 Overall many studies, including the three RCTs that this paper focuses on, evaluate the 
effects of exogenous melatonin on the many patient groups with disturbed circadian rhythms.1 In 
some previous studies, short-term supplementation has been shown to alleviate problems, but the 
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studies included in this systematic review evaluate long term supplementation on patients with 
chronic disease and its results.  
Objective 
The objective of this selective EBM review is to determine whether or not “Does 
exogenous melatonin improve quality of sleep in patients experiencing sleep disturbances 
secondary to chronic diseases?” 
Methods 
 This selective EBM review analyzed 3 randomized control studies that evaluated the 
aforementioned objective. The population criteria that were set for the purpose of this systematic 
review included the following: participants ages 18 and older, diagnosis of a chronic disease 
such kidney disease or major depression, and reported subjective findings of sleep disturbances. 
All three randomized controlled studies used exogenous melatonin as the intervention addressed, 
and used a placebo tablet for the comparison control group. The main outcome that is evaluated 
in this paper is quality of sleep based on sleep questionnaires values.  
 This writer used PubMed as the sole data source to find the three studies utilized in this 
paper, using keywords of melatonin, depression, and hemodialysis. The search parameters used 
were: English language, human species data, and published in peer reviewed journal in the past 
10 years. Types of studies searched included only randomized control studies, which measured 
outcomes that could be classified as a POEM or Patient Oriented Evidence that Matters. 
Exclusion criteria included any studies in which participants used melatonin previously, studies 
that tested melatonin along with other pharmacological methods, or studies including participants 
not suffering from chronic diseases. The search conducted also verified that there are no previous 
Cochrane reviews or systematic reviews published on this objective, or any published by other 
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previous students. All studies used in this paper used p-values to report statistics. The 
demographics and characteristics of the included studies can be seen in Table 1.  
Table 1 - Demographics & Characteristics of included studies 
Study Type # 
Pts 
Age 
(yrs.) 
Inclusion 
Criteria 
Exclusion Criteria W/D Interventions 
Serfaty1 
(2010) 
Double 
blind 
RCT 
33 18-65 Diagnostic and 
Statistical 
Manual of 
Mental 
Disorders 
classification for 
major 
depression; a 
score of >17 on 
BDI; self 
reported sleep of 
1 hour less than 
normal at least 3 
days per week  
Another axis 1 
diagnosis, 
delusions or 
hallucinations, 
ECT within 6 
months, hypnotic 
medications, 
recent change in 
dose or type of 
psychotropic 
medication within 
4 weeks, history of 
ETOH abuse 
2 Slow release 
exogenous 
melatonin  
(6 mg)  
Russcher2 
(2013) 
Double 
blind 
RCT 
67 18-85 Patient in age 
group with >3 
months of 
hemodialysis 
with adequate 
dialysis efficacy; 
subjective sleep 
problems at 
baseline; mean 
sleep onset 
latency > 15 
min.  
Current melatonin 
use, Known 
hypersensitivity to 
melatonin, sever 
psychological or 
neurological 
disease, unstable 
angina pectoris, 
NYHA class IV 
heart failure, 
pregnancy, 
participation in 
another clinical 
trial 1 month prior 
to start of this 
study 
25 3 mg IR 
melatonin 
QD at 22:00 
hrs. 
Koch6 
(2008) 
Double 
blind 
RCT 
20 18-85 Pts in age group 
on stable 
hemodialysis (> 
3 months)  
Pts with prior use 
of melatonin, use 
of hypnotics that 
could not be 
stopped, or sever 
psychological or 
neurological 
disease.  
4 Melatonin 3  
mg QD at 
22:00 hrs.  
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Outcomes Measured 
Outcomes measured in the three studies included in this paper were POEMS. In the 
Serfaty et al. RCT, subjective measures of sleep were collected using the Leeds Sleep Evaluation 
Questionnaire which measured: getting to sleep, quality of sleep, awakening from sleep and 
behavior following waking.1 In the Russcher et al. RCT study, sleep-wake characteristics were 
measured from the Dutch sleep disorders questionnaire which recorded estimated sleep time, 
daytime function, sleep onset latency, wake periods during the night, feeling rested during 
daytime, and subjective sleep quality.2 In the Koch et al. RCT study, sleep disturbances were 
measured by quality of life questionnaire.6 
Results 
 In the study by Serfaty et al., out of the 203 interviewed potential participants, 33 patients 
were recruited to the study.1 16 of the participants were referred to the study by their general 
practitioner, 13 were identified by databases, and 4 were self referred.1 Two participants dropped 
out immediately due to feeling much better. Participants were randomly assigned to one of two 
groups, which was done by independent coordinator ensuring a double-blind trial.1 The LSEQ 
tested many parameters for sleep and determined that sleep improved for whole group, but not 
specifically to the experimental group with melatonin. General Linear Modeling was used in this 
study to measure the differences between the placebo and melatonin groups which showed that 
there was a significant reduction in time getting to sleep (F = 6.6, d.f. = 3.2, P < 0.001) and 
improved quality of sleep (F = 4.8, d.f. = 3.6, P < 0.002) with melatonin.1 Other than the 
previous two values mentioned, no other significant differences in sleep were seen in either 
group.1  
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 In the Serfaty RCT, some patients reported adverse effects in both the melatonin and 
placebo groups. The adverse effects reported are shown in Table 2.  
Table 2 – Adverse Effects seen in Serfaty RCT1 
Melatonin Group Placebo group 
Adverse Effect # of patients 
affected 
Adverse Effect # of patients 
affected 
Vivid dreams 2 Poor sleep  2 
Daytime Somnolence 1 Daytime Somnolence 1 
Fuzzy feeling  1 Vivid Dreams 1 
  Headaches  1 
 
 The Russcher et al. RCT included sixty-seven daytime hemodialysis patients, forty-two 
of whom completed the study.2 Twenty-five patients did not complete the study, reasons for 
which can be seen in Table 3. This RCT sought patients who had been on hemodialysis for at 
least 3 months, and reported subjective sleep problems with a minimum mean sleep onset latency 
of > 15 minutes.2 Quality of life was the main topic investigated in this study, using a 
questionnaire that was independently filled out by the participants on a daily basis after sleep 
periods. After analyzing the questionnaire data, the researchers concluded that there was no 
discernable differences in vitality between the melatonin and placebo groups over the 12 months 
(difference -1.9%, 95% CI – 12.6, 8.7).2 Some incidental differences were found which 
illustrated increased general mental health (difference 9.3%, 95% CI -0.1, 18.7, P = 0.052), and 
decreased physical functioning (-11.4%, 95 CI -12.6, 8.7) in the melatonin group over 12 
months.2 All other parameters tested by the quality of life questionnaire did not differ between 
melatonin and placebo groups. No side effects of melatonin were reported.2 
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Table 3 – Patient Dropouts in Russcher et al. RCT2 
Melatonin Group Placebo group 
Reason for leaving # of patients  Reason for leaving  # of patients  
Died  3 Died 3 
Transplantation  3 Transplantation  3 
Withdrawal 4 Withdrawal 6 
Nocturnal dialysis  1 Nocturnal dialysis  1 
  Home dialysis  1 
 
 The RCT by Koch et al. had a total of twenty-four participants at baseline, but 20 
participants remained at the end of the 18-week period.6 Of the 4 participants lost, two patients 
died, one withdrew from having dialysis, and one was removed due to non-compliance.6 
Throughout the course of the study, no adverse effects of melatonin were reported.  
 Koch et al. evaluated quality of sleep using a sleep questionnaire that analyzed daytime 
function and subjective sleep experience. The results of the questionnaire from patients 
undergoing hemodialysis are summarized in Table 4. The data illustrated that less time was 
necessary to fall asleep for patients on daytime dialysis when using melatonin over the placebo 
group (P = 0.04).6 Overall sleep time increased as well on nights after dialysis (P=0.01), and 
nighttime awakenings decreased after dialysis (P=0.03).6 No adverse effects were reported.  
Table 4 – Sleep Questionnaire results from Koch et al.6 
Parameters  Median Placebo Median Melatonin 
Daytime napping (min) 30 0 
Sleep onset latency (min) 45 15 
Wake periods (min) 30 25 
Sleep time (min) 345 480 
 
Discussion 
  
Of the three RCT studies incorporated in this paper, only the Koch et al. RCT showed 
significant improvement due to the use of supplemental exogenous melatonin in those suffering 
with chronic diseases. The RCT by Serfaty et al. did not show any significant difference in sleep 
quality between both the melatonin and placebo groups, despite very similar demographic 
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factors, depression severity, and randomization. Serfaty et al. also discusses a limitation in which 
the values from the sleep diary/questionnaire could unreliable as they may have not been always 
accurately reported by the patients.1 It can be recommended in this RCT that such subjective 
findings be recorded or collected by a third party instead of having patients answering the 
questionnaires independently. The RCT by Russcher et al. also did not show any significant 
positive effects of using exogenous melatonin. The authors found that there was no improved 
quality of life based on the quality of life questionnaire it utilized, but did suggest using a higher 
dosage of melatonin could produce more favorable results.2 Limitations of the Russcher study 
also include the higher than expected drop out rate of participants (37%), as this could have 
affected the data in a negative manner. The authors only expected to have a 25% drop out rate, 
and argued that the results obtained could be due to the study’s loss of power rather than the 
inefficacy of exogenous melatonin to alleviate sleep disturbances.2   
As this selective EBM review analyzes the efficacy of exogenous melatonin on sleep 
disturbances secondary to chronic disease, future research should be done on the effect of 
exogenous melatonin on diseases other than CKD and depression. The search conducted by this 
author on PubMed did not reveal many RCTs regarding the efficacy on exogenous melatonin in 
general, and future RCT and researchers should seek out other chronic diseases that can impact 
the circadian rhythms of humans.  
Conclusion 
 After reviewing each of the three RCT studies discussed in this systematic review, there 
is not enough data for a conclusive decision on if exogenous melatonin is effective in alleviating 
sleep disturbances in those suffering from chronic diseases. Although all three RCTs 
incorporated in this paper had rigorous methodology and adequate sample sizes, 2/3 studies did 
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not find significant results supporting a positive change in sleep patterns in participants. The 
Koch et al. RCT did show definitive results that indicated exogenous melatonin improved quality 
of sleep by reducing time needed to get to sleep, increase in sleep time, and improvement in 
sleep quality. Limitations of this systematic review include one study that had a high number of 
withdrawals (25), biases of the participants filling out the subjective sleep questionnaires 
themselves, and the overall use of the standard dose of melatonin versus a larger dose.  
Therefore, further research should be conducted on the benefit of melatonin on patients suffering 
from chronic kidney disease, but should also include many different types of dialysis rather than 
only patients undergoing daytime treatments. Future studies can also investigate more long-term 
effects of melatonin and the effects of a larger does of melatonin, as all three RCTs in this paper 
utilized traditional doses of melatonin and did not exceed a timeline of 12 months.  
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